8-K filed with the SEC on 2026-10-13.
Zoetis announced the appointment of veteran media and global consumer business leader Iris Knobloch to its Board of Directors, effective December 1, 2026, expanding its board to 13 members.
Zoetis has officially declared its fourth quarter 2026 dividend for its shareholders. This regular financial update signals continued capital return to investors.
8-K filed with the SEC on 2026-10-08.
Zoetis published new head-to-head veterinary research in Parasites & Vectors demonstrating that Simparica Trio offers superior protection against drug-resistant heartworm isolates compared to competing products, informing clinical decision support for veterinarians.
An analyst argues that Zoetis is currently undervalued by the market and presents a strong buying opportunity. This positive valuation perspective could boost investor confidence in the company's financial health.
The Zoetis Foundation announced new grants in four countries including Japan to support veterinary professionals. This initiative does not meet the English-language requirement for the investor.
Zoetis announced it will host a conference call and webcast to discuss its third quarter 2026 financial results. This upcoming earnings release is critical for investors tracking the company's financial health and performance.
A new market research report highlights Zoetis alongside other major players in the growing global veterinary drugs market. This reflects the company's strong baseline financial standing and broad product portfolio across animal health sectors.
An investment analysis highlights concerns regarding companion animal weakness at Zoetis, suggesting caution for investors. This weakness could impact near-term financial performance and valuation multiples for the company.
An equity research article evaluates Zoetis as an undervalued compounder with strong long-term prospects. This analysis highlights market perceptions and valuation metrics critical for investors tracking the company's financial health.
An equity analysis examines how new market competition alters the investment narrative for Zoetis while maintaining its current rating. This assessment provides insight into competitive dynamics affecting the company's market position.
An analysis of Zoetis's market position, noting that long-term growth is supported by structural pet trends and a growing veterinary diagnostics segment despite near-term macro pressures.
Zoetis has updated its Vetscan Imagyst platform to include blood parasite detection and improved cell classification. This expansion strengthens the company's veterinary diagnostics and AI-driven clinical tools portfolio.
Zoetis executives presented at the Morgan Stanley Healthcare Conference to discuss business strategy and market outlook. This provides investors with direct insights into the company's financial health and operational goals.
At the Morgan Stanley 24th Annual Global Healthcare Conference, Zoetis management addressed softer near-term demand in companion animal care while emphasizing the long-term strength of its broad R&D pipeline in areas like diagnostics, oncology, and chronic conditions.
Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →